N-(2-Pyrazinylcarbonyl)-L-phenylalanyl-N-[(1R)-1-borono-3-hydroxy-3-methylbutyl]-L-phenylalaninamide is an impurity of Bortezomib (B675700); the first proteasome inhibitor to be approved by the US FDA for multiple myeloma, a blood cancer.